A phase II study of temozolemide vs. procarbazine in patients with glioblastoma multiforme at first relapse

British Journal of Cancer

Volumn 83, Issue 5, 2000, Pages 588-593

  Yung, W K A ^a   Albright, R E ^b   Olson, J ^c   Fredericks, R ^d   Fink, K ^e   Prados, M D ^f   Brada, M ^g   Spence, A ^h   Hohl, R J ⁱ   Shapiro, W ^j   Glantz, M ^k   Greenberg, H ^l   Selker, R G ^m   Vick, N A ⁿ   Rampling, R ^o   Friedman, H ^p   Phillips, P ^q   Bruner, J ^a   Yue, N ^r   Osoba, D ^s   Zaknoen, S ^t   Levin, V A ^a   more..

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g ROYAL MARSDEN HOSPITAL   (United Kingdom)

^h UNIVERSITY OF WASHINGTON   (United States)

ⁱ UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^j BARROW NEUROLOGICAL INSTITUTE   (United States)

^k Memorial Hospital of Rhode Island   (United States)

^l UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^m WESTERN PENNSYLVANIA HOSPITAL   (United States)

ⁿ EVANSTON HOSPITAL   (United States)

^o BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^p DUKE UNIVERSITY MEDICAL CENTER   (United States)

^q HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^r MRI Reading Center at St Joseph   (United States)

^s BRITISH COLUMBIA CANCER AGENCY   (Canada)

^t MERCK RESEARCH LABORATORIES   (United States)

more..

Author keywords

Glioblastoma multiforme; Malignant glioma; Procarbazine; Temozolomide

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; PROCARBAZINE; STEROID; TEMOZOLOMIDE;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER GROWTH; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; FITNESS; GLIOBLASTOMA; HEADACHE; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RASH; THROMBOCYTOPENIA; VOMITING;

EID: 0033897173     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1054/bjoc.2000.1316     Document Type: Article

References (30)

1. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Fletchner H, Fleishman SB and de Haes JC (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85: 365-376
2. Bleehen NM, Newlands ES, Lee SM, Thatcher N, Selby P, Calvert AH, Rustin GJS, Brampton M and Stevens MFG (1995) Cancer research campaign phase II trial of temozolomide in metastatic melanoma. J Clin Oncol 13: 910-913
3. Bower M, Newlands ES, Bleehen NM, Brada M, Begent RJH, Calvert H, Colquhoun I, Lewis P and Brampton MH (1997) Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma. Cancer Chemother Pharmacol 40: 484-488
4. Brada M, Thomas DGT, Bleehen NM, Roberts JT, Senanayake F, Abram P, Lantos PL, Moss TH, Ironside JW, Whaley JB and Stenning SP (1998) Proceedings of the American Society of Clinical Oncology 17: [Abstract 1543]
5. Brock CS, Matthews JC, Brown G, Luthra SK, Brady F, Newlands ES and Price P (1996) The kinetic behaviour of temozolomide in man. Proceedings of the American Society of Clinical Oncology 15: 475 [Abstract 1502]
6. 11C-temozolomide uptake by human recurrent high grade astrocytomas. Br J Cancer 75: 1241 [Abstract]
7. Burger PC, Vogel FS, Green SB and Strike TA (1985) Glioblastoma multiforme and anaplastic astrocytoma. Pathologic criteria and prognostic implications. Cancer 56: 1106-1111
8. Chamberlain MC and Kormanik PA (1998) Practical guidelines for the treatment of malignant gliomas. West J Med 168: 114-120
9. Fayers P, Aaronson N, Bjordal K and Sullivan M (1995) EORTC QLQ-C30 Scoring Manual. Brussels, Belgium, Quality of Life Unit, EORTC Data Centre
10. Fine HA, Dear KB, Loeffler JS, Black PM and Canellos GP (1993) Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant glioma in adults. Cancer 71: 2585-2597
11. Feun LG, Savaraj N and Landy HJ (1994) Drug resistance in brain tumors. J Neurooncol 20: 165-176
12. Forsyth PA and Cairncross JG (1996) Chemotherapy for malignant gliomas. Baillières Clin Neurol 5: 371-393
13. Jaeschke R, Singer J and Guyatt GH (1989) Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials 10: 407-415
14. Juniper EF, Guyatt GH, Willan A and Griffith LE (1994) Determining a minimal important change in a disease-specific quality of life questionnaire. J Clin Epidemiol 47: 81-87
15. King MT (1996) The interpretation of scores from the EORTC quality of life questionnaire QLQ-C30. Qual Life Res 5: 555-567
16. Kumar ARV, Renaudin J, Wilson CB, Buldrey EB, Enot KJ and Levin VA (1974) Procarbazine hydrochloride in the treatment of brain tumors. J Neurosurg 40: 365-371
17. Levin VA, Leibel SA and Gutin PH (1997) Neoplasms of the central nervous system. In: DeVita Jr VT, Hellman S, Rosenberg SA, (eds). Cancer Principals and Practice iof Oncology, 5th ed. Philadelphia: Lippincott Raven: 2041-2042
18. McComb RD and Burger PC (1985) Pathologic analysis of primary brain tumors. Neurol Clin 3:711-728
19. Newlands ES, Blackledge GRP, Slack JA, Rustin GJS, Smith DB, Stuart NSA, Quarterman CP, Hoffman R, Stevens MFG, Brampton MH and Gibson AC (1992) Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). Br J Cancer 65: 287-291
20. Newlands ES, O'Reilly SM, Glaser MG, Bower M, Evans H, Brock C, Brampton MH, Colquhoun I, Lewis P, Rice-Edwards JM, Illingworth RD and Richards PC (1996) The Charing Cross Hospital experience with temozolomide in patients with gliomas. Eur J Cancer 32A: 2236-2241
21. Newton HB, Junck L, Bromberg J, Page MA and Greenberg HS (1990) Procarbazine chemotherapy in the treatment of recurrent malignant astrocytomas after radiation and nitrosourea failure. Neurology 40: 1743-1746
22. O'Reilly SM, Newlands ES, Glaser MG, Brampton M, Rice-Edwards JM, Illingworth RD, Richards PG, Kennard C, Colquhoun IR, Lewis P and Stevens MFG (1993) Temozolomide: a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours. Eur J Cancer 29A: 940-942
23. Osoba D, Aaronson NK, Muller M, Sneeuw K, Hsu M-A, Yung WKA, Brada M and Newlands E (1996) The development and psychometric validation of a brain cancer quality-of-life questionnaire for use in combination with general cancer-specific questionnaires. Qual Life Res 5: 139-150
24. Osoba D, Aaronson N, Zee B, Sprangers M and te Velde A (1997) Modification of the EORTC QLQ-C30 (version 2.0) based on content validity and reliability testing in large samples of patients with cancer. Qual Life Res 6: 103-108
25. Osoba D, Rodrigues G, Myles J, Zee B and Pater J (1998) Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 16: 139-144
26. Patel M, McCully C, Godwin K and Balis F (1995) Plasma and cerebrospinal fluid pharmacokinetics of temozolomide. Proceedings of the American Society of Clinical Oncology 14: 461 [Abstract 1485]
27. Rodriguez LA, Prados M, Silver P and Levin VA (1989) Reevaluation of procarbazine for the treatment of recurrent malignant central nervous system tumours. Cancer 64: 2420-2423
28. Stevens MFG, Hickman JA, Langdon SP, Chubb D, Viekers L, Stone R, Baig G, Goddard C, Gibson NW, Slack JA, Newton C, Lunt E, Fizames C and Lavelle F (1987) Antitumor activity and pharmacokinetics in mice of 8-Carbamoyl-3-methylimidazo [5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045: M & B 39831), a novel drug with potential as an alternative to dacarbazine. Cancer Res 47: 5846-5852
29. Tsang LLH, Farmer PB, Gescher A and Slack JA (1990) Characterisation of urinary metabolites of temozolomide in humans and mice and evaluation of their cytotoxicity. Cancer Chemother Pharmacol 26: 429-436
30. Ware JE Jr, Kosinski M and Keller SD (1998-copyright) SF-36 Physical and Mental Health Summary Scales: A User's Manual [Homepage of Quality Metric], [Online]. Available: http://www.qmetric.com/products/manuals/SF-36-Summary.php3 [1999, March 1]